Clinical trial · Observational
Changes in Reproductive and Sexual Health in People With Early Onset Colorectal Cancer
The Effects of Chemotherapy or Radiotherapy on Reproductive and Sexual Health of Early Onset Colorectal Cancer Patients
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to find out how cancer treatments (chemotherapy and/or radiation therapy) affect reproductive and sexual health in people with early onset colorectal cancer. The study researchers will observe and track changes in hormone levels and in sexual and reproductive health in people with early onset colorectal cancer. This information will help researchers know more about how cancer treatments affect reproductive and sexual health, including the ability to have children (fertility).
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Colorectal Cancer | Malignant Colorectal Neoplasm | CURATED_BROADER | 0.80 |
| Colorectal Carcinoma | Colorectal Carcinoma | ONTOLOGY_EXACT | 0.98 |
| Colorectal Neoplasms | Colorectal Neoplasm | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Hormone biomarker analysis | Diagnostic Test | — | UNRESOLVED |
| QoL Questionnaires | Behavioral | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- label
- Participants with Colon Cancer
- description
- This patient population will have hormone biomarker analysis, questionnaire (QOL) administration, and, if the patient is male, semen analysis
- interventionNames
- Diagnostic Test: Hormone biomarker analysis
- Behavioral: QoL Questionnaires
- label
- Participants with Rectal Cancer
- description
- This patient population will have hormone biomarker analysis, QOL administration, and, if the patient is male, semen analysis
- interventionNames
- Diagnostic Test: Hormone biomarker analysis
- Behavioral: QoL Questionnaires
Primary outcomes (2)
- measure
- Change in anti-Mullerian hormone (AMH), estradiol and FSH of oxaliplatin-induced gonadal toxicity in pre-menopausal female patients (<40y)
- timeFrame
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 50 Years
Show eligibility criteria text
Inclusion Criteria: * 18-40 years of age and premenopausal (female) or 18-50 years of age (male) at time of diagnosis * Histologic diagnosis of colorectal adenocarcinoma * Able and willing to participate in the informed consent process * Eligible for curative adjuvant or neoadjuvant therapy for colon or rectal cancer * Willing and able to complete protocol questionnaires * Rectal patients only: Individuals who will be receiving chemotherapy, followed by chemoradiotherapy (ChemoRT) Exclusion Criteria: * Prior systemic treatment for this malignancy * Active or prior secondary malignancy * History of ovarian resection (if female) * Pregnant or nursing (lactating) women, where pregnancy is defined as the state of a female after conception until the termination of gestation, confirmed by a positive hCG laboratory test.
References
Publications (0)
Data not yet available